A new generation of therapeutic modalities

Jun 8, 2020 | Biopharma, Blogs, Pharma | 0 comments

There are over 7,000 genetic diseases that could potentially be cured using gene therapy. Rare metabolic diseases, autoimmune disorders, cardiovascular disease and cancers are some of the top disease classes that can be addressed with gene therapies. With over 1,000 clinical trials involving gene therapies or oligonucleotides currently in various stages, and 11 gene therapy drugs already on the market, it is clear the potential benefit to human health is profound.

This new generation of therapeutic modalities presents unprecedented technological challenges in bringing therapies to patients. These challenges have affected both the speed and ultimate cost of bringing new therapies to market, with many gene therapeutics now categorized as some of the most expensive medications currently in existence. Ultimately, there is a lack of sufficient tools as we seek faster and more accurate methods for characterizing these new classes of drugs.

Although faced with many unique challenges and still at its very early stages, the global gene therapy market is growing rapidly. As of 2019, the size of this market is estimated to be more than $1 billion, and it is expected to expand at a compound annual growth rate (CAGR) of 32%. This growth is primarily driven by an increase in the number of clinical trials, the amount of government and private funding and the number of partnerships between small biotech and large pharmaceutical companies.

This type of growth brings many opportunities, and to take advantage of them, it is crucial that you are prepared with solutions to the challenges ahead. To help you succeed, we invite you to download a copy of the gene therapy and oligonucleotide compendium. This compendium was created with you in mind, and it aims to provide you with precision analytics that will help bring your therapies to market faster.

The compendium includes:

  • An overview of current trends and the market landscape
  • Workflows and approaches to purity testing, sizing sequencing and expression analysis
  • Strategies for better understanding the biological impact of genetic mutations and specific gene editing events
  • Discover how to accelerate your gene therapy and oligonucleotide development by getting the right answers the first time through precise analytics you can trust.

Download now >

PFAS FAQ’s: Ask our experts

As PFAS testing continues to expand, laboratories face increasing pressure to deliver reliable results at lower detection limits and faster turnaround times. While much of the conversation focuses on analytical methods and regulations, maintaining instrument performance and minimizing downtime are equally critical to success.

How LC-MS laboratories in regulated environments can build a strong foundation for reliable data, audit readiness and lifecycle control

Whether supporting pharmaceutical quality control, bioanalysis, clinical research, environmental testing, or food safety applications, regulated laboratories share a common responsibility: ensuring reliable data, maintaining audit readiness, and controlling systems throughout their lifecycle. Yet when compliance discussions arise, attention often moves quickly to audits, documentation, electronic records, and standard operating procedures. These elements are essential, but they depend on a more fundamental question: Can the analytical system consistently produce reliable results?

Future-proofing pesticide testing: Why speed is becoming a competitive advantage

Food testing laboratories face growing pressure. Pesticide panels continue to expand, regulations evolve, and customers still expect fast turnaround times at a competitive cost.

Posted by

0 Comments

Submit a Comment

Pin It on Pinterest

Share This

Share this post with your network